Explore liraglutide dosage trends, reconstitution volumes, and vial size patterns from WPA peptide calculator sessions for the only daily-injectable GLP-1 agonist.
Liraglutide is the only daily-injectable GLP-1 receptor agonist that has been formally approved, marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting liraglutide.
Liraglutide has the deepest published clinical record of any modern GLP-1 receptor agonist, anchored across three distinct programs that together span type 2 diabetes, chronic weight management, and cardiovascular outcomes. 8mg against active comparators including glimepiride, rosiglitazone, glargine, and exenatide. 8mg target. 0mg/day), and SCALE Maintenance (weight-loss maintenance after a low-calorie diet lead-in). 4mg. 8 years and reported about a 13% reduction in major adverse cardiovascular events — the first time any GLP-1 receptor agonist demonstrated a cardiovascular benefit, and the result that opened the door for the larger SUSTAIN-6, SELECT, and SURPASS-CVOT programs in the years that followed.
Liraglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk. It was FDA-approved as Victoza for type 2 diabetes in 2010 and as Saxenda for chronic weight management in 2014, making it the first once-daily GLP-1 analog used clinically and the structural ancestor of semaglutide.
Liraglutide binds the GLP-1 receptor with high affinity, slowing gastric emptying, amplifying glucose-dependent insulin release, suppressing glucagon, and reducing appetite through hypothalamic signalling. A C-16 fatty-acid sidechain enables reversible albumin binding, extending the half-life to ~13 hours and supporting once-daily subcutaneous dosing — shorter than semaglutide or tirzepatide.
The LEAD program established A1C reductions of ~1.0–1.5% in T2D. SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015) reported ~8.0% mean weight loss at 56 weeks on 3.0mg daily. LEADER (Marso et al., NEJM 2016) showed a 13% reduction in major adverse cardiovascular events in T2D with high CV risk. Pediatric weight-management approval (SCALE Teens) extended the label to adolescents in 2020.
Liraglutide has a reported half-life of ~13 hours, and the dose intervals researchers model most often fall around once daily. A ~13-hour half-life is why liraglutide is dosed once daily rather than weekly — it accumulates modestly over a couple of days but is largely cleared between doses if one is missed. It is catalogued under Weight Loss on WPA.
2 Liraglutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 300mcg (1 calculations). The median dose across all sessions is 600mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (2 sessions).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.